Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On January 20, 2017, Nuo Therapeutics, Inc. (the “Company”) announced that quotation of its common stock, par value $0.0001 per share (the “Common Stock”), will commence on OTCQB on January 20, 2017 under the trading symbol “AURX.” The Company is working towards upgrading to OTCQX, the highest tier of OTCMarkets, although it cannot provide any assurances that it will be able to meet the conditions for quotation on OTCQX.

The shares of Common Stock are not yet eligible for Deposit/Withdrawal At Custodian (“DWAC”) trading through The Depository Trust Company (“DTC”). DWAC trading allows brokers and custodial banks to make electronic book-entry deposits and withdrawals of shares of Common Stock into and out of their DTC book-entry accounts using a “Fast Automated Securities Transfer” service. While the Company’s transfer agent is applying for DWAC eligibility for the shares of Common Stock, the Company can provide no assurances that this eligibility will be obtained. Likewise, the Company can provide no assurances that the Common Stock will continue to trade on OTCQB, that broker-dealers will continue to provide public quotes of the Common Stock on this market, or that the trading volume of the Common Stock will be sufficient to provide for an efficient trading market.

Cautionary Statement Regarding Forward-Looking Statements

The statements contained in this Current Report on Form 8-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 31E of the Securities Exchange Act of 1934, including statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future, including without limitation its expectations with respect to obtaining DWAC eligibility or its plans with respect to upgrading to OTCQX. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. All forward-looking statements included in this document are based on information available to the Company on the date hereof and the Company assumes no obligation to update any such forward-looking statement. Prospective investors should also consult the risks described from time to time in the Company’s Reports on Forms 10-K, 10-Q and 8-K and Annual Reports to Shareholders.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this Form 8-K shall not be deemed an admission as to the materiality of any information herein that is required to be disclosed solely by Regulation FD.

About Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ)

Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Recent Trading Information

Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) closed its last trading session at 0.0120 with 51,009 shares trading hands.